Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL-286, a novel retinoic acid receptor-β agonist for treatment of spinal cord injury, in male healthy participants.
Journal Information
Full Title: Br J Clin Pharmacol
Abbreviation: Br J Clin Pharmacol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"CONFLICT OF INTEREST STATEMENT The authors declare no competing financial interests. MBG and J.P.T.C have a matter of composition patent for KCL‐286."
"Funding information This work was funded by Medical Research Council (MRC), UK (Grant ref. no MR/R006466/1) to J.P.T.C. M.B.G., A.M., T.M., J.H. and H.H."
"The present study is a phase 1, first‐in‐human double blind, randomized, placebo‐controlled trial, in male healthy volunteers, consisting of a single ascending dose (SAD) adaptive design with a food interaction (FI) arm, and a multiple ascending dose (MAD) design, to evaluate the safety, tolerability, PK and pharmacodynamics (PD) of KCL‐286. (Trial ID: https://www.isrctn.com/ISRCTN12424734, registration date, 18/07/2018)."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025